{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-007301","form_type":"8-K","ticker":"PMDI","cik":"0000806517","company_name":"PSYCHEMEDICS CORP","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.614879+00:00","generated_at":"2026-06-22T02:21:32.476029+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Psychemedics Q3 revenue down 3% to $6.5M, net loss of $0.1M; declares $0.07 dividend","bullets":["Revenue $6.5M vs $6.7M YoY (-3%); net loss $0.1M ($0.02/sh) vs net income $0.7M ($0.13/sh).","Nine-month revenue $19.5M (+5% YoY); net loss $0.4M ($0.07/sh) vs net income $1.0M ($0.17/sh).","Quarterly cash dividend of $0.07/sh declared, payable Dec 16, 2022 to holders of record Dec 2, 2022.","Prior-year quarter included $1.0M Employee Retention Credit; excluding ERC, gross margins were flat.","Cash $3.5M at Sep 30, 2022, up from $2.0M at Dec 31, 2021; equipment financing reduced to $0.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-007301","json":"https://secwatch.observer/filing/0001171843-22-007301.json","markdown":"https://secwatch.observer/filing/0001171843-22-007301.md","text":"https://secwatch.observer/filing/0001171843-22-007301.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/806517/000117184322007301/0001171843-22-007301-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/806517/000117184322007301/f8k_110922.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T02:21:32.476029+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0534b88e7decda0d2ef8662a6ef4bc87bdbdd5bc","claim":"PSYCHEMEDICS CORP reported the third quarter ended September 30, 2022 results: revenue $6.5 million, net income $0.1 million, EPS ($0.02) per diluted share.","evidence_excerpt":"The Company’s revenue for the quarter ended September 30, 2022, was $6.5 million versus $6.7 million for the quarter ended September 30, 2021, a decrease of 3%. Net loss for the quarter ended September 30, 2022, was $0.1 million or ($0.02) per diluted share, versus net income of $0.7 million or $0.13 per diluted share, for the comparable quarter last year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/806517/000117184322007301/0001171843-22-007301-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$6.5 million"},{"label":"Net income","value":"$0.1 million"},{"label":"EPS","value":"($0.02) per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e17b94ec4aac718cf23fac3be00a6ef55c200402","claim":"PSYCHEMEDICS CORP reported the nine months ended September 30, 2022 results: revenue $19.5 million, net income $0.4 million, EPS ($0.07) per diluted share.","evidence_excerpt":"The Company’s revenue for the nine months ended September 30, 2022, was $19.5 million versus $18.5 million for the comparable period in 2021, an increase of 5%. Net loss for the nine months ended September 30, 2022, was $0.4 million or ($0.07) per diluted share, versus net income of $1.0 million or $0.17 per diluted share, for the comparable period last year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/806517/000117184322007301/0001171843-22-007301-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the nine months ended September 30, 2022"},{"label":"Revenue","value":"$19.5 million"},{"label":"Net income","value":"$0.4 million"},{"label":"EPS","value":"($0.07) per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}